(Q46887329)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579813%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579813%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579813%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Shu-Wen Lin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579813%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Han-Yueh Kuo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579813%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Po-Ren Hsueh

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579813%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

Chung-Chih Lai

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579813%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Kuan-Yeh Lee

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579813%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Yen-Hsu Chen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579813%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

3 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579813%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anti-infective Therapy

9 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579813%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579813%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579813%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

401-417

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579813%20AND%20SRC:MED&resulttype=core&format=json

Management of community-acquired pneumonia: a review and update

9 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Clinical policy: critical issues in the management of adult patients presenting to the emergency department with community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Burden of community-acquired pneumonia in North American adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Epidemiology of community-acquired pneumonia in adults: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Approaches to estimate the population-based incidence of community acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Trends in mortality and medical spending in patients hospitalized for community-acquired pneumonia: 1993-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Community-acquired pneumonia as an emergency: time for an aggressive intervention to lower mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Long-term prognosis in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Community-acquired pneumonia guidelines: a global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Prevalence of methicillin-resistant staphylococcus aureus as an etiology of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

A worldwide perspective of atypical pathogens in community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Diagnostic tests for agents of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Does empiric therapy for atypical pathogens improve outcomes for patients with CAP?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Is activity against "atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Guidelines for the management of adult lower respiratory tract infections--full version

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Clinical effects of gemifloxacin on the delay of tuberculosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Macrolide resistance in bacteremic pneumococcal disease: implications for patient management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

What is the relevance of antimicrobial resistance on the outcome of community-acquired pneumonia caused by Streptococcus pneumoniae? (should macrolide monotherapy be used for mild pneumonia?).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

How important is methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia and what is best antimicrobial therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

In vitro activities of three nonfluorinated quinolones against representative bacterial isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

A liquid chromatography-tandem mass spectrometry assay for the determination of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, in human plasma and urine and its application to a single-dose pharmacokinetic study in healthy Chinese volunt

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Levofloxacin in the treatment of community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Application of fluoroquinolone pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Antimicrobial safety: focus on fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Ibis T5000: a universal biosensor approach for microbiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.894881

10.1586/14787210.2014.894881

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579813%20AND%20SRC:MED&resulttype=core&format=json

release_uouhnd36mvdcvfcwau4jz3ft3u

9 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/uouhnd36mvdcvfcwau4jz3ft3u

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference